United States securities and exchange commission logo




                                                                                
                              February 15, 2024

       Amro Albanna
       Chief Executive Officer
       Aditxt, Inc.
       737 N. Fifth Street, Suite 200
       Richmond, VA 23219

                                                        Re: Aditxt, Inc.
                                                            Amendment No. 2 to 
Registration Statement on Form S-1
                                                            Filed February 14, 
2024
                                                            File No. 333-276588

       Dear Amro Albanna:

                                                        We have reviewed your 
amended registration statement and have the following comment.

              Please respond to this letter by amending your registration 
statement and providing the
       requested information. If you do not believe this comment applies to 
your facts and
       circumstances or do not believe an amendment is appropriate, please tell 
us why in your
       response.

              After reviewing any amendment to your registration statement and 
the information you
       provide in response to this letter, we may have additional comments. 
Unless we note otherwise,
       any references to prior comments are to comments in our February 12, 
2024 letter.

       Amendment No. 2 to Registration Statement on Form S-1

       Prospectus Summary
       Recent Developments
       Merger Agreement with Evofem Biosciences, Inc. , page 7

   1.                                                   We have read your 
response to prior comment 1 in which you indicate that the conditions
                                                        to close outlined in 
your letter, as well as termination clauses and the impending loan to
                                                        Evofem, deem the merger 
not to be probable at this time. However, we note your
                                                        disclosure in Item 9.01 
of Form 8-K filed on December 12, 2023 stating that, in
                                                        accordance with the 
Item, you would file financial statements and pro forma financial
                                                        information, with 
respect to the transaction, by amendment to the Form 8-K not later than
                                                        71 calendar days after 
the date the Form 8-K is required to be filed. Based on the status of
                                                        your merger activities 
to date and your disclosure in the 8-K, please provide us with
                                                        additional details as 
to why you do not believe the merger is probable at this time.
 Amro Albanna
Aditxt, Inc.
February 15, 2024
Page 2

       Please contact Tracie Mariner at 202-551-3744 or Mary Mast at 
202-551-3613 if you
have questions regarding comments on the financial statements and related 
matters. Please
contact Jimmy McNamara at 202-551-7349 or Tim Buchmiller at 202-551-3635 with 
any other
questions.



                                                        Sincerely,
FirstName LastNameAmro Albanna
                                                        Division of Corporation 
Finance
Comapany NameAditxt, Inc.
                                                        Office of Life Sciences
February 15, 2024 Page 2
cc:       Sean F. Reid, Esq.
FirstName LastName